Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes

医学 危险系数 2型糖尿病 内科学 胃肠病学 肝硬化 肝病 临床终点 肝移植 糖尿病 置信区间 内分泌学 移植 临床试验
作者
Chia‐Chih Kuo,Min‐Hsiang Chuang,Chun‐Hsien Li,Ya‐Wen Tsai,Po‐Yu Huang,Hsing‐Tao Kuo,Chih‐Cheng Lai
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:61 (7): 1163-1174 被引量:23
标识
DOI:10.1111/apt.18502
摘要

BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated long-term liver benefits in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). However, no direct comparison between these therapies has been conducted. This study aimed to compare major adverse liver outcomes (MALOs) between GLP-1 RAs and SGLT2is in patients with MASLD and T2D. METHODS: Using the TriNetX Research Network, a multinational and multi-institutional database, we identified adults with MASLD and T2D who received their first prescription for either a GLP-1 RA or an SGLT2i between January 2010 and June 2023. We conducted a propensity score-matched (PSM) cohort study comparing new users of GLP-1 RAs and SGLT2is. The primary outcome was the risk of MALOs, a composite endpoint consisting of decompensated cirrhosis events, hepatocellular carcinoma, and liver transplantation. Secondary outcomes included all-cause mortality and individual components of the primary outcome. RESULTS: This study included 15,176 pairs of patients treated with either a GLP-1 RA or a SGLT2i. The adjusted hazard ratio (HR) for MALO associated with GLP-1 RAs relative to SGLT2is was 0.84 (95% confidence interval [CI]: 0.73-0.97; incidence rate: 88.9 versus 105.3 events per 10,000 person-years), primarily driven by reduction in decompensated cirrhosis events (adjusted HR: 0.83, 95% CI: 0.71-0.96). GLP-1 RAs were associated with lower all-cause mortality (adjusted HR: 0.84, 95% CI: 0.75-0.94). CONCLUSION: GLP-1 RAs are associated with better long-term liver outcomes compared to SGLT2is in patients with MASLD and T2D.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
平常梦桃完成签到,获得积分10
1秒前
持刀的辣条应助听忆采纳,获得10
1秒前
歪歪发布了新的文献求助10
1秒前
雪球宝宝完成签到,获得积分10
2秒前
3秒前
3秒前
4秒前
bean应助raditivecooling采纳,获得10
4秒前
852应助raditivecooling采纳,获得10
4秒前
研友_VZG7GZ应助Dobby采纳,获得10
5秒前
5秒前
上官若男应助拼搏姒采纳,获得10
6秒前
桐桐应助沫沫采纳,获得10
6秒前
SciGPT应助拜楞严采纳,获得10
6秒前
彭于晏应助小巧的冰烟采纳,获得10
7秒前
treasure完成签到,获得积分10
7秒前
7秒前
Kyle发布了新的文献求助10
8秒前
自觉安白完成签到,获得积分10
9秒前
田小冉发布了新的文献求助10
10秒前
盼芙发布了新的文献求助10
10秒前
11秒前
Lyz完成签到,获得积分20
11秒前
12秒前
12秒前
晨芒完成签到,获得积分10
12秒前
洋洋洋关注了科研通微信公众号
13秒前
安详的御姐完成签到,获得积分10
14秒前
kaifangfeiyao发布了新的文献求助10
14秒前
14秒前
15秒前
GXL完成签到,获得积分10
15秒前
16秒前
思源应助任慧娟采纳,获得10
16秒前
英姑应助蛋蛋采纳,获得10
16秒前
OrangeLight发布了新的文献求助10
17秒前
Qi发布了新的文献求助10
17秒前
可爱的函函应助anztlan采纳,获得10
17秒前
孙成成发布了新的文献求助10
17秒前
envdavid完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
晶种分解过程与铝酸钠溶液混合强度关系的探讨 8888
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6422829
求助须知:如何正确求助?哪些是违规求助? 8241583
关于积分的说明 17518910
捐赠科研通 5476830
什么是DOI,文献DOI怎么找? 2893111
邀请新用户注册赠送积分活动 1869494
关于科研通互助平台的介绍 1706898